论文部分内容阅读
目的:探讨含吡柔比星联合方案治疗复发、难治非霍奇金淋巴瘤(NHL)的临床疗效。方法:23 例复发、难治NHL患者,应用EPOTH加环孢菌素A(CsA)方案化疗:长春新碱(VCR)0.4 mg·m-2·d-1,足叶乙苷(VP16)50 mg·m-2·d-1,吡柔比星(THP蛳ADM)20 mg·m-2·d-1,上述药物均在第1 天~ 第4 天连续96 h静脉滴注;环磷酰胺(CTX)600 mg·m-2·d-1,第5 天静脉推注;强的松(PED)60 mg·m-2·d-1,第1天~第7天,每日8 时顿服;CsA 8 mg/kg,化疗前12 h及化疗后第1天~第5天,各服1 次。计算CR率及有效率,并与以往采用TCOP方案治疗的24 例复发、难治NHL患者的疗效作回顾性比较。结果:EPOTH+CsA方案组的疗效高于TCOP方案组的疗效(P<0.05)。结论:EPOTH+CsA方案长时间低剂量持续静脉输注治疗复发、难治的NHL是安全的,有较好的疗效,其远期效果有待进一步观察。
Objective: To investigate the clinical efficacy of combination therapy with pirarubicin in the treatment of relapsed and refractory non-Hodgkin’s lymphoma (NHL). Methods: Twenty-three patients with relapsed and refractory NHL were treated with EPOTH plus cyclosporin A (CsA): vincristine (VCR) 0.4 mg · m-2 · d-1, VP16 50 mg · m-2 · d-1, and THP 蛳 ADM 20 mg · m-2 · d-1. The drugs were intravenously dripped continuously for 96 h from day 1 to day 4; (CTX) 600 mg · m-2 · d-1 on the 5th day, PED 60 mg · m-2 · d-1 on day 1 to day 7 Time service; CsA 8 mg / kg, 12 h before chemotherapy and day 1 to day 5 after chemotherapy, each serving 1 time. The CR rate and the effective rate were calculated and compared with the results of 24 patients with recurrent or refractory NHL treated with TCOP regimen in the past. Results: The efficacy of the EPOTH + CsA regimen group was higher than that of the TCOP regimen group (P <0.05). Conclusion: EPOTH + CsA regimen is a safe and effective refractory NHL for long-term, low-dose continuous intravenous infusion. The long-term and long-term effects need further observation.